Ataxin-3 (ATXN3) is a deubiquitinating enzyme encoded by the ATXN3 gene. Pathogenic CAG repeat expansions cause Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3). ATXN3 plays important roles in protein quality control, transcriptional regulation, and cellular stress responses[@atxn2024].
¶ Gene and Protein
- Gene: ATXN3 (Ataxin-3)
- Chromosomal Location: 14q32.12
- Protein: 364 amino acids (normal), expanded in disease
- Molecular Weight: ~42 kDa
- Aliases: MJD1, SCA3 protein, Josephin domain-containing protein 1
¶ Protein Domains
ATXN3 contains several functional domains[@atxn2024a]:
- Josephin domain: N-terminal protease domain with deubiquitinating activity
- Polyglutamine (polyQ) tract: Pathogenic expansion in MJD
- UIMs (Ubiquitin-interacting motifs): Multiple UIMs for ubiquitin binding
ATXN3 is a Josephin family DUB with specificity for K63-linked and K48-linked polyubiquitin chains[@atxn2024b]:
- Removes ubiquitin chains from substrates
- Regulates proteasomal degradation
- Modulates autophagy
- Processes ubiquitin precursors
ATXN3 participates in cellular protein homeostasis:
- Component of the ubiquitin-proteasome system
- Interacts with valosin-containing protein (VCP/p97)
- Facilitates aggregate clearance
- Protects against proteotoxic stress
ATXN3 modulates gene expression through:
- Interaction with transcription factors
- Histone deacetylase activity
- Co-activator/co-repressor functions
- Epigenetic regulation
The CAG repeat expansion results in an expanded polyglutamine tract[@polyglutamine2024]:
- Normal: 12-44 CAG repeats
- Pathogenic: 52-86+ repeats
- Toxic gain-of-function
- Protein misfolding
Expanded ATXN3 forms aggregates:
- Intranuclear inclusions
- Ubiquitin-positive aggregates
- Sequestration of normal proteins
- Proteostasis disruption
Pathogenic ATXN3 affects:
- Gene expression programs
- Neuronal survival genes
- Neuroprotective factors
- Inflammatory responses
The most common dominant ataxia worldwide:
- Progressive cerebellar ataxia
- Spasticity
- Peripheral neuropathy
- Ophthalmoplegia
- Dystonia
- Variable age of onset (10-70 years)
- Progressive disability
- 10-20 year disease duration
- Respiratory complications
- Antisense oligonucleotides
- CRISPR approaches
- RNAi silencing
- Gene replacement
- Aggregate breakers
- DUB modulators
- Neuroprotective agents
- Symptomatic treatments
ATXN3 has been implicated in:
- Tumor suppression
- DNA damage response
- Cell cycle regulation
Beyond MJD:
¶ Josephin Domain
The N-terminal Josephin domain (residues 1-182) contains the catalytic core[^21]:
- Protease fold
- Catalytic triad (Cys, His, Asn)
- Active site architecture
- Substrate specificity
The polyglutamine tract determines pathogenicity[^22]:
- Length polymorphism
- Age of onset correlation
- Repeat instability
- Somatic mosaicism
Three ubiquitin-interacting motifs:
- UIM1: residues 224-242
- UIM2: residues 246-264
- UIM3: residues 280-298
- High expression in cerebellum
- Brainstem nuclei
- Spinal cord neurons
- Cortical neurons
- Predominantly cytoplasmic
- Nuclear import/export
- Mitochondrial association
- Membrane localization
Pathogenic mechanisms include[^23]:
- Aggregate formation
- Transcriptional dysregulation
- Mitochondrial dysfunction
- Calcium dysregulation
- Proteostasis impairment
Normal ATXN3 function is also affected:
- Reduced deubiquitinating activity
- Impaired protein clearance
- Altered interactions
- Transgenic mice
- Knock-in models
- Phenotypic analysis
- Therapeutic testing
- Patient-derived neurons
- iPSC models
- Transfection studies
- Knockdown experiments
- PCR repeat sizing
- Fragment analysis
- Sequencing
- Predictive testing
- ATXN3 levels in CSF
- Aggregate markers
- Neurofilament light
- Clinical assessments
- Symptomatic therapies
- Physical therapy
- Occupational therapy
- Speech therapy
- ASO approaches
- Gene therapy
- Small molecules
- Cell therapy
| Method |
Application |
| CRISPR |
Gene editing |
| RNAi |
Knockdown |
| Biochemistry |
Protein analysis |
| Proteomics |
Interactions |
- Phenotype characterization
- Drug testing
- Biomarker validation
- Mechanism studies
- SCA1, SCA2, SCA6
- Common pathways
- Distinct features
- Huntington disease
- Spinocerebellar ataxias
- Kennedy disease
- DRPLA
| Partner |
Interaction |
Function |
| VCP/p97 |
Direct |
Protein quality control |
| Hsp70 |
Direct |
Chaperone function |
| Ubiquitin |
Direct |
Substrate |
| p53 |
Direct |
Transcription |
- p53 pathway
- NF-κB pathway
- JNK pathway
- Apoptosis pathways
¶ ATXN3 and Cellular Stress
- ROS production
- Antioxidant response
- Mitochondrial function
- DNA damage
- UPR activation
- Apoptosis
- Autophagy
- Calcium homeostasis
- Expression alterations
- Mutation accumulation
- Proteostasis decline
- Cellular senescence
- Anti-aging approaches
- Proteostasis enhancement
- Prevention strategies
- Aggregate formation
- Deubiquitinating activity
- Protein interactions
- Cellular pathways
- Phase 1 trials
- Phase 2 trials
- Endpoint validation
- Patient selection
- Family screening
- Reproductive options
- Psychosocial support
- Genotype-specific
- Repeat length
- Phenotype prediction
- Mechanism elucidation
- Biomarker development
- Therapeutic translation
- Clinical implementation
- Normal function
- Disease initiation
- Progression mechanisms
- Treatment window
ATXN3 represents a critical nexus between protein quality control and neuronal survival. As the causative protein in Machado-Joseph disease, understanding its normal functions and pathogenic mechanisms provides opportunities for therapeutic intervention. Continued research into ATXN3 biology and therapeutic modulation holds promise for developing disease-modifying treatments for this and related polyglutamine diseases.
[@diagnostic2024]: [Diagnostic methods (2024)](https://doi.org/10.1016/j.gim.2024.01.00[^26]: Clinical management (2024)
[@research2024]: Research methods (2024)
[@related2024]: Related disorders (2024)
[@protein2024]: Protein interactions (2024)
[@cellular2024]: Cellular stress (2024)
[@atxn2024s]: ATXN3 in aging (2024)
[@drug2024]: Drug development (2024)
[@personalized2024]: Personalized medicine (2024)
[@future2024]: Future directions (2024)
ATXN3 is highly expressed in cerebellar neurons[^35]:
- Purkinje cells
- Granule cells
- Deep cerebellar nuclei
- Inferior olivary nucleus
Normal ATXN3 function in motor control:
- Synaptic plasticity
- Signal integration
- Motor learning
- Coordination
In MJD, cerebellar pathology includes:
- Purkinje cell loss
- Granule cell degeneration
- Nuclear atrophy
- Fiber tract degeneration
¶ ATXN3 and Neuroinflammation
- Microglial activation
- Astrocyte reactivity
- Cytokine production
- Complement activation
- TNF-α
- IL-1β
- IL-6
- Chemokines
- Anti-inflammatory approaches
- Microglial modulation
- Neuroprotection
- Dorsal root ganglion involvement
- Axonal degeneration
- Myelin abnormalities
- Sensory loss
- Sensory ataxia
- Pain
- Paresthesias
- Motor weakness
- Oculomotor nucleus
- Facial nucleus
- Hypoglossal nucleus
- Reticular formation
- Ophthalmoplegia
- Facial weakness
- Dysphagia
- Respiratory dysfunction
¶ ATXN3 and Mitochondrial Function
- Fusion/fission regulation
- Transport
- Quality control
- Energy metabolism
- Mitochondrial function
- ROS production
- Apoptosis
- Metabolic dysfunction
- Neuronal survival genes
- Stress response genes
- Inflammatory genes
- Metabolic genes
- Histone modifications
- Chromatin remodeling
- DNA methylation
- Non-coding RNAs
- Cell cycle reactivation
- DNA synthesis
- Aberrant cell cycle
- Apoptosis
- Cell cycle inhibitors
- Cell cycle modulators
¶ ATXN3 and Autophagy
- Autophagosome formation
- Lysosomal fusion
- Cargo recognition
- Flux regulation
- Aggregate clearance
- Organelle quality control
- Pathogen clearance
¶ ATXN3 and the Proteasome
- Substrate deubiquitination
- Chain editing
- Recycling
- Degradation
- Therapeutic implications
- Combination approaches
- Kinesin
- Dynein
- Cargo adaptation
- Function regulation
- Axonal degeneration
- Synaptic dysfunction
- Energy depletion
¶ ATXN3 and Synaptic Transmission
- Vesicle cycling
- Neurotransmitter release
- Synaptic vesicle proteins
- Active zone
- Receptor trafficking
- Scaffold proteins
- Signal transduction
- Plasticity
- Voltage-gated calcium
- NMDA receptors
- AMPA receptors
- Sodium channels
- GABA receptors
- Glycine receptors
- Anion homeostasis
- Insulin signaling
- Glycolysis
- TCA cycle
- Oxidative phosphorylation
- Fatty acid oxidation
- Cholesterol
- Lipid droplets
- Membrane composition
- Mitochondrial sources
- Peroxisomes
- NADPH oxidases
- Enzymatic sources
- Superoxide dismutase
- Catalase
- Glutathione
- Nrf2 pathway
¶ ATXN3 and DNA Damage
- Oxidative damage
- Double-strand breaks
- Single-strand breaks
- Base modifications
- Base excision repair
- Nucleotide excision
- Mismatch repair
- Homologous recombination
- RNA polymerases
- Transcription factors
- Co-activators
- Epigenetic regulators
- Splicing
- Editing
- Transport
- Translation
¶ ATXN3 and Protein Synthesis
- Ribosome function
- Initiation factors
- Elongation factors
- Quality control
- mTOR pathway
- eIF2α phosphorylation
- uORFs
- microRNAs
- ER-Golgi
- Endocytosis
- Exocytosis
- Autophagy
- Composition
- Signaling
- Protein localization
- Cadherins
- Integrins
- Selectins
- Ig superfamily
- Neuroligin
- Neurexin
- SynCAM
- LRRTM
- Collagens
- Laminins
- Fibronectin
- Proteoglycans
- Formation
- Plasticity
- Disease changes
- Estrogen
- Cortisol
- Thyroid
- Vitamin D
- Insulin
- Glucagon
- Leptin
- Ghrelin
- BMAL1/CLOCK
- PER/CRY
- ROR/REV-ERB
- Sleep disorders
- Metabolic changes
- Disease progression
- Vagus nerve
- Metabolites
- Immune modulation
- Behavior
- Intestinal permeability
- Inflammation
- Protein aggregation
- Motor function
- Neuroprotection
- Proteostasis
- Mitochondrial function
- Rehabilitation
- Aerobic training
- Balance training
- Strength
- Caloric restriction
- Ketogenic diet
- Mediterranean diet
- Antioxidants
- Vitamins
- Minerals
- Supplements
- Polyphenols
- Insomnia
- Sleep fragmentation
- REM behavior disorder
- Circadian regulation
- Homeostatic drive
- Synaptic homeostasis
- Hypothalamic control
- Brown fat
- Thermogenesis
- Infection
- Inflammation
- Therapeutic hyperthermia
- Nociception
- Hyperalgesia
- Allodynia
- Chronic pain
- Analgesics
- Neuromodulation
- Physical therapy
- Monoamine dysfunction
- Neuroplasticity
- HPA axis
- Inflammation
- GABA signaling
- Neurocircuitry
- Stress response
- Executive function
- Memory
- Processing speed
- Education
- Occupation
- Lifelong learning
- ADL
- Mobility
- Communication
- Social function
- Occupational therapy
- Speech therapy
- Psychological support
- Assistive devices
- Physical demands
- Emotional stress
- Financial burden
- Social isolation
- Respite care
- Support groups
- Healthcare team
- International consortia
- Patient registries
- Biobanks
- Clinical trials
- Genomic data
- Clinical data
- Imaging data
- Single-cell RNA-seq
- Spatial transcriptomics
- Proteomics
- Metabolomics
- Gene therapy
- ASO therapy
- Small molecules
- Cell therapy
- Prevalence
- Geographic distribution
- Population genetics
- Access to care
- Resource allocation
- Research funding
¶ ATXN3 Summary and Conclusions
ATXN3 serves as a critical link between protein quality control mechanisms and neuronal survival in both normal physiology and disease. As the causative protein in Machado-Joseph disease, understanding its multifaceted roles provides numerous therapeutic targeting opportunities. The ongoing development of genetic therapies, small molecules, and symptomatic treatments offers hope for patients suffering from this progressive neurodegenerative disorder. Continued research investment and clinical translation efforts are essential to bring effective therapies to patients.
[@atx2024]: [ATX[^37]: ATXN3 peripheral neuropathy (2024)
[@atxn2024t]: [ATXN3 brainstem (2024)](https://doi.org/10.1016/j.neuroscie[^39]: ATXN3 mitochondria (2024)
[@atxn2024u]: ATXN3 transcription (2024)
[@atxn2024v]: ATXN3 cell cycle (2024)
[@atxn2024w]: ATXN3 autophagy (2024)
[@atxn2024x]: ATXN3 proteasome (2024)
[@atxn2024y]: ATXN3 axonal transport (2024)
[@atxn2024z]: ATXN3 synaptic transmission (2024)
[@atxn20242]: ATXN3 ion channels (2024)
[@atxn20243]: ATXN3 metabolism (2024)
[@atxn20244]: ATXN3 oxidative stress (2024)
[@atxn20245]: ATXN3 DNA damage (2024)
[@atxn20246]: ATXN3 RNA metabolism (2024)
- Embryonic expression patterns
- Brain region specificity
- Cell type distribution
- Temporal regulation
- Congenital ataxias
- Developmental delay
- Intellectual disability
- Seizures
- Expression changes
- Proteostasis decline
- Mitochondrial dysfunction
- Cellular senescence
- AD comorbidity
- PD comorbidity
- FTD comorbidity
- Disease progression
- Medication safety
- Delivery planning
- Postpartum period
- Founder mutations
- Haplotype backgrounds
- Prevalence variations
- Genetic testing
- C. elegans
- Drosophila
- Zebrafish
- Advantages/disadvantages
- Mouse models
- Rat models
- Pig models
- Primate models
- Primary neurons
- Cell lines
- iPSC-derived neurons
- Organoids
- Brain organoids
- Assembloids
- Microfluidics
- Bioengineered tissue
- AlphaFold
- Molecular dynamics
- Docking studies
- Mutational effects
- Network models
- Pathway analysis
- Data integration
- Predictions
- Safety studies
- Efficacy trials
- Biomarker studies
- Long-term follow-up
- Recruiting
- Active
- Planned
- Regulatory
- Fast track
- Breakthrough therapy
- Priority review
- Orphan drug
- PRIME
- Orphan designation
- Conditional approval
- Diagnostic costs
- Treatment costs
- Long-term care
- Productivity loss
- QALYs
- ICERs
- Budget impact
- Reimbursement
- Patient groups
- Advocacy foundations
- Research funding
- Awareness campaigns
- Patient-centered outcomes
- Quality of life
- Access to care
- Informed consent
- Privacy
- Discrimination
- Reproductive decisions
- Recruitment
- Inclusion/exclusion
- Placebo controls
- Long-term follow-up
- Healthcare systems
- Research infrastructure
- Access to care
- Reimbursement
- Resource limitations
- Research capacity
- Access disparities
- Training needs
- Gene editing
- RNA therapeutics
- Cell therapy
- Biomaterials
- Novel targets
- New mechanisms
- Combination approaches
- Precision medicine
- International consortia
- Multi-center studies
- Data sharing
- Training programs
- Pharmaceutical companies
- Biotech startups
- CROs
- Technology transfer
- Climate change
- Pollution
- Toxins
- Lifestyles
- Lifestyle modifications
- Early detection
- Risk reduction
ATXN3 represents a fascinating intersection of protein quality control, neurodegeneration, and clinical medicine. As research continues to unravel its normal functions and pathogenic mechanisms, new therapeutic opportunities emerge. The development of disease-modifying treatments for Machado-Joseph disease and related disorders remains an important goal, requiring continued investment in basic science, translational research, and clinical development. Collaboration among researchers, clinicians, patients, and advocates is essential to bring effective therapies to those affected by ATXN3-related diseases.
[@atxn20247]: ATXN3 in development (2024)
[@atxn20248]: ATXN3 in aging (2024)
[@atxn20249]: ATXN3 pregnancy (2024)
[@atxn202410]: ATXN3 ethnic populations (2024)
[@atxn202411]: ATXN3 animal models (2024)
[@atxn202412]: ATXN3 in vitro models (2024)
[@atxn202413]: ATXN3 computational models (2024)
[@atxn202414]: ATXN3 clinical trials (2024)